EMEA-002536-PIP01-18-M03 - paediatric investigation plan

Lebrikizumab

Key facts

• Active Substance:
  Lebrikizumab
• Therapeutic area:
  Dermatology
• Decision number:
  P/0134/2023
• PIP number:
  EMEA-002536-PIP01-18-M03
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of atopic dermatitis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  13/04/2023

Decision

P/0134/2023 EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (EMEA- 002536-PIP01-18-M03)

Reference Number: P/0134/2023